Header Ads Widget

White House Withdraws Nomination of Dr. Heidi Overton to Lead the FDA

 


White House Withdraws Nomination of Dr. Heidi Overton to Lead the FDA

WASHINGTON — The White House withdrew the nomination of Dr. Heidi Overton to serve as commissioner of the Food and Drug Administration (FDA) on Tuesday evening, pulling the plug on her candidacy just hours before a pivotal Senate committee vote.

Overton, a physician and deputy director of the White House Domestic Policy Council, was tapped by President Donald Trump in August to replace former FDA Commissioner Marty Makary, who stepped down in May. However, her nomination stalled on Capitol Hill amid mounting skepticism from both Senate Democrats and key Republican lawmakers, leaving her short of the votes needed to advance.

"She lacks the support on the Hill to move forward with her confirmation," a senior administration official confirmed.

Wavering Republican Support Scuttles Committee Vote

The withdrawal came on the eve of a scheduled Wednesday morning vote by the Senate Health, Education, Labor, and Pensions (HELP) Committee. With Republicans holding a razor-thin one-seat majority on the panel and all 11 Democrats expected to oppose her, even a single GOP defection would have defeated Overton's nomination in committee.

Several Republican senators raised significant doubts during and after Overton’s September confirmation hearing:

  • Managerial and Vaccine Concerns: HELP Committee Chairman Sen. Bill Cassidy (R-La.) openly questioned whether Overton possessed sufficient executive experience to manage a sprawling federal agency grappling with staffing and morale challenges. Cassidy also criticized her support for an executive order seeking to break up combination childhood vaccines, such as the measles, mumps, and rubella (MMR) shot, calling the stance "almost disqualifying".

  • Abortion Pill and Vaping Policies: Sen. Josh Hawley (R-Mo.) expressed frustration after Overton sidestepped questions regarding a delayed safety review of the abortion medication mifepristone. Meanwhile, moderate Republicans—including Sens. Susan Collins (R-Maine) and Lisa Murkowski (R-Alaska)—remained uncommitted ahead of the vote, with Murkowski pressing Overton over her unclear stance on mifepristone regulation.

  • Internal Conservative Friction: Her candidacy also exposed divides within the administration’s broader health coalition, with critics aligned with Health and Human Services Secretary Robert F. Kennedy Jr.’s "Make America Healthy Again" (MAHA) movement viewing her as misaligned with their priorities, particularly regarding her work on administration vaping policies.

A Narrowing Window for FDA Leadership

Overton’s exit leaves the FDA under the continued stewardship of Acting Commissioner Kyle Diamantas, who has led the agency since Makary’s departure.

The collapse of the nomination complicates the White House's broader push to fill top federal posts before Senate Democrats assume control of the chamber in January following the recent midterm elections. With limited legislative days remaining on the Senate calendar, confirming a permanent FDA chief before the power shift faces steep logistical hurdles.

Administration officials have already begun vetting potential replacements. Among the names circulating in Washington is outgoing Kansas Sen. Roger Marshall—a physician who recently lost his reelection bid—though the White House is also weighing whether to rely on acting leadership to bypass a contentious confirmation battle.

Post a Comment

0 Comments